Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Building an Individual Brand: Illustrations from Forces to be reckoned with - 2Reveal Less popular Authentic Realities You Didn't Learn in School
- 3Coffee Prices Finish Higher on Brazil Cop Concerns
- 4Manual for Instructive Application for Youngsters
- 5Most loved Specially prepared Espresso Mix: Which Meal Do You Adore the Most?
- Geminid shooting stars: One of 2025's most exciting meteor showers begins tonight
- The risk of falling space junk hitting airplanes is on the rise, experts warn
- The most effective method to Augment Benefits in Gold Speculation: Systems and Tips
- Eleven arrested over mass shooting in South Africa tavern
- Europe's powerful Ariane 6 rocket launches Sentinel-1D Earth-observation satellite to orbit (video)
- 12 times rockets and spacecraft crashed and burned in 2025
- The Best 15 Applications for Efficiency and Association
- Dominating Your Cash: The Fundamental Manual for Overseeing Individual accounting records
- Flourishing in a Remote Workplace: Individual Techniques
